Oak Hill Wealth Advisors LLC reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,573 shares of the company’s stock after selling 384 shares during the period. Johnson & Johnson makes up 1.4% of Oak Hill Wealth Advisors LLC’s portfolio, making the stock its 16th biggest position. Oak Hill Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $4,230,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Atlantic Private Wealth LLC purchased a new stake in Johnson & Johnson during the 1st quarter valued at $32,000. 25 LLC purchased a new stake in Johnson & Johnson in the first quarter worth about $55,000. Horizons Wealth Management lifted its position in shares of Johnson & Johnson by 1,730.0% in the second quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after acquiring an additional 346 shares in the last quarter. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson during the second quarter worth $66,000. Finally, Sanctuary Wealth Management L.L.C. purchased a new position in Johnson & Johnson during the 2nd quarter valued at approximately $109,000. 68.40% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on JNJ. Barclays upped their target price on Johnson & Johnson from $158.00 to $162.00 and gave the company an “equal weight” rating in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, October 9th. HSBC initiated coverage on shares of Johnson & Johnson in a report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price target for the company. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 10th. Finally, Credit Suisse Group increased their target price on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.00.
Insider Activity at Johnson & Johnson
In other news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $156.85 on Monday. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04. The company has a market capitalization of $407.65 billion, a P/E ratio of 31.75, a price-to-earnings-growth ratio of 3.21 and a beta of 0.55. The firm has a 50-day moving average price of $163.10 and a two-hundred day moving average price of $162.57.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.59 earnings per share. As a group, research analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were given a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 3.03%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- How to Invest in Biotech Stocks
- MarketBeat Week in Review – 10/9 – 10/13
- Dividend Payout Ratio Calculator
- What BlackRock’s Earnings Tell You About The Stock Market Tide
- Are Penny Stocks a Good Fit for Your Portfolio?
- Sociedad Quimica y Minera de Chile Well Positioned Lithium Stock
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
